Komori
Immuno-Biological Laboratories (4570) · InitiativeContinuing to improve the production efficiency of Human-Type Collagen III

Preparations for the Sale of NeoSilk Human-Type Collagen III

First written in FY2019. 2 of 5 entries say "Advanced", first in FY2021. Latest entry: FY2025.

5entries
7years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2019 – FY2020AdvancedFY2021 – FY20232019: 120192020: 120202021: 120212022: 020222023: 120232024: 020242025: 12025
Same theme, other companies

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2025Continuing to improve the production efficiency of Human-Type Collagen IIIAnnual report

    「Sales of the cosmetic ingredient “Neo Silk®-Human-Type Collagen III” have begun, but because production efficiency is uneven, the company is working to improve it.」

    After beginning sales, the company has continued to improve the production efficiency of Human-Type Collagen III to address the issue of uneven production efficiency.
  2. FY2023AdvancedAnnual report

    「Sales of the cosmetic ingredient “Neo Silk®-Human-Type Collagen III” have begun. Going forward, the company will develop premium cosmetics using “Neo Silk®-Human-Type Collagen III” and products that can be offered to a broad range of users.」

    After beginning sales of Human-Type Collagen III as a raw material, the company moved on to developing applications for premium cosmetics and developing products.
  3. FY2021AdvancedAnnual report

    「Sales of the cosmetic ingredient “Neo Silk®-Human-Type Collagen III” have begun. Going forward, the company will develop premium cosmetics using “Neo Silk®-Human-Type Collagen III” and products that can be offered to a broad range of users.」

    Human-Type Collagen III progressed from the preparation stage to the start of sales, followed by the development of premium cosmetics using the ingredient.
  4. FY2020RestatedAnnual report

    「The company is also preparing to sell Collagen Type III (baby collagen), “Neo Silk® Human-Type Collagen III,” as a new cosmetic ingredient.」

    The company continues to prepare for the sale of Neo Silk Human-Type Collagen III and pursue its inclusion in the Flevan series.
  5. FY2019First statedAnnual report

    「The company is also preparing to sell Collagen Type III (baby collagen), “Neo Silk® Human-Type Collagen III,” as a new cosmetic ingredient.」

    The company began preparing to sell Human-Type Collagen III (baby collagen) as a new cosmetic ingredient derived from genetically modified silkworms.
Moved together

"Expansion of Therapeutic and Diagnostic Drug Pipelines" moved the same way as this thread, in the same document, in 2 of its 5 moves.

222222★123456
  1. ★This thread
  2. 1Expansion of Therapeutic and Diagnostic Drug Pipelines2×
  3. 2Improving Profitability Through a Change in the Sales Policy for the Diagnostics and Reagents Business2×
  4. 3Securing Earnings and Focusing Management Resources2×
  5. 4Foreign Exchange Rate Risk2×
  6. 5Narrowing Operating Losses and Continued Losses2×
  7. 6Development of the CTP Measurement System as an In Vitro Diagnostic Product2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Immuno-Biological Laboratories yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.